| advanced breast cancer (metastatic) | versus No demonstrated result for efficacy | 6 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | |
| Trial | Treatments | Patients | Method |
|---|
| Nomura, 1993 | (n=-9) vs. (n=-9) | patients with advanced or recurrent breast cancer | double-blind Sample size: -9/-9 Primary endpoint: FU duration: | | Gershanovich, 1997 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Milla-Santos, 2001 | toremifene (TOR) 60 mgs/dayly/o.r. (n=-9) vs. tamoxifen (TAM) 40 mgs/dayly/o.r. (n=-9) | postmenopausal women with advanced breast cancer, without previous systemic therapy | double-blind Sample size: -9/-9 Primary endpoint: FU duration: | | Hayes, 1995 | toremifene (TOR; 60 mg/d [TOR60] and 200 mg/d (n=-9) vs. tamoxifen (TAM; 20 mg/d) (n=215) | postmenopausal patients with hormone receptor-positive or -unknown metastatic breast cancer | Sample size: -9/215 Primary endpoint: FU duration: | | Stenbygaard, 1993 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Pyrhonen, 1997 | (n=-9) vs. (n=-9) | post-menopausal patients with advanced breast cancer who have not had prior systemic therapy | Sample size: -9/-9 Primary endpoint: FU duration: |
|
